profit from every $100 of sales.
$0$100
Cardio Diagnostics Holdings
$1.89+1.07% today
-44.4% in 1 year
1-year low $1.051-year high $6.55
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cardio Diagnostics Holdings sold, what it kept, and what it did with the cash.
Sales went from $950 in 2022 to $14,825 in 2025, with -$6.50 million of profit last year.
SalesProfit
Cardio Diagnostics Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cardio Diagnostics Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cardio Diagnostics Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -5 | -7 | -8 | -6 | |
| -5 | -2 | -8 | -6 | |
| -5 | -8 | -8 | -6 | |
| -45.30 | -19.80 | -9.35 | -3.71 | |
| – | – | – | – | |
| -478,784.3% | -42,440.4% | -23,977.9% | -43,737.5% | |
| -490,630.0% | -49,087.8% | -24,028.2% | -43,832.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6 | 4 | 11 | 8 |
| Cash | 4 | 1 | 8 | 5 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 2 | 2 | 1 | 1 |
| 4 | 3 | 10 | 7 | |
| 0 | 0 | 1 | 2 | |
| -71.5% | -30.7% | -62.8% | -66.8% | |
| -108.4% | -283.2% | -87.7% | -93.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -6 | -5 | -6 | |
| 0 | 1 | 0 | 0 | |
| -5 | -6 | -5 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 1 | 3 | 0 |
Valuation
- –
- –
- –
- 0.5×
- 377.3×
- –
- –
- -109.9%
- -116.2%
- 0.0%
Profitability
- -2,180.2%
- -43,737.5%
- -43,832.5%
- -41,051.9%
- -84.5%
- -102.3%
- -71.7%
- -83.7%
- -90.5%
- 5,649.5%
Growth
- +149.9%
- –
- −9.6%
- –
- +53.3%
Financial health
- -0.7×
- 0.10
- 9.0%
- -438.1×
- 9.79
- 9.79
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 946
Top 3%of 867
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.63 | – | – |
| Mar 13, 2026 | -0.80 | -1.80 | +55.6% |
| Nov 12, 2025 | -0.98 | -1.80 | +45.6% |
| Aug 14, 2025 | -0.97 | -1.80 | +46.1% |
| May 15, 2025 | -0.97 | -1.80 | +46.1% |
| Mar 20, 2025 | -0.01 | -0.06 | +83.3% |
| Nov 13, 2024 | -0.06 | -0.15 | +60.0% |
| Aug 12, 2024 | -0.06 | -0.11 | +45.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
78Pass
Philip Fisher
34No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
42No pass
Terry Smith
39No pass
Questions about Cardio Diagnostics Holdings
Is Cardio Diagnostics Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cardio Diagnostics Holdings AI analysis
What does Cardio Diagnostics Holdings do?
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. It is in Biotechnology.
Does Cardio Diagnostics Holdings pay a dividend?
No. Cardio Diagnostics Holdings does not pay a dividend at the moment.
Is Cardio Diagnostics Holdings stock halal?
No. Cardio Diagnostics Holdings does not pass our halal screen: its cash and confirmed interest-bearing investments are 91% of its market value, at or above the 33% limit. How we check
How has Cardio Diagnostics Holdings stock done over the past year?
Down 44.4% over the past twelve months, to $1.89. It traded between $1.05 and $6.55 and is 71.1% below its high.
Who are Cardio Diagnostics Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cardio Diagnostics Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.